{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:54:59Z","timestamp":1784274899738,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13283-x","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:00:36Z","timestamp":1753909236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4511-4801","authenticated-orcid":false,"given":"Pedro Henrique","family":"de Souza Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7839-7422","authenticated-orcid":false,"given":"Felipe Alves","family":"de Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0176-7077","authenticated-orcid":false,"given":"Julia Scaramal","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6756-3567","authenticated-orcid":false,"given":"Anna Lydia Machado","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6240-9295","authenticated-orcid":false,"given":"Larissa Emi","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6447-9724","authenticated-orcid":false,"given":"Fernanda Moraes","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2960-631X","authenticated-orcid":false,"given":"Let\u00edcia Hanna Moura","family":"da Silva Gattas Graciolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3869-7373","authenticated-orcid":false,"given":"Artur Menegaz","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"13283_CR1","volume-title":"Harrison\u2019s principles of internal medicine","author":"BAC Cree","year":"2018","unstructured":"Cree BAC, Hauser SL (2018) Multiple Sclerosis. In: Jameson JL, Fauci AS, Kasper DL et al (eds) Harrison\u2019s principles of internal medicine, 20th edn. McGraw-Hill Education, New York, NY","edition":"20"},{"key":"13283_CR2","unstructured":"Multiple sclerosis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multiple-sclerosis. Accessed 26 Jun 2025"},{"key":"13283_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"13283_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue E-W, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545\u2013556. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3","journal-title":"Lancet Neurol"},{"key":"13283_CR5","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133:1380-1390.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049","journal-title":"Am J Med"},{"key":"13283_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"13283_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","volume":"39","author":"YD Fragoso","year":"2019","unstructured":"Fragoso YD, Adoni T, Gomes S et al (2019) Severe exacerbation of multiple sclerosis following withdrawal of fingolimod. Clin Drug Investig 39:909\u2013913. https:\/\/doi.org\/10.1007\/s40261-019-00804-6","journal-title":"Clin Drug Investig"},{"key":"13283_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","volume":"16","author":"B Merkel","year":"2017","unstructured":"Merkel B, Butzkueven H, Traboulsee AL et al (2017) Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev 16:658\u2013665. https:\/\/doi.org\/10.1016\/j.autrev.2017.04.010","journal-title":"Autoimmun Rev"},{"key":"13283_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A et al (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75:320\u2013327. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"key":"13283_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"13283_CR11","doi-asserted-by":"publisher","first-page":"CD011381","DOI":"10.1002\/14651858.CD011381.pub3","volume":"1","author":"M Gonzalez-Lorenzo","year":"2024","unstructured":"Gonzalez-Lorenzo M, Ridley B, Minozzi S et al (2024) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 1:CD011381. https:\/\/doi.org\/10.1002\/14651858.CD011381.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"13283_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liao Q, Wen H, Zhang Y (2021) Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev 20:102826. https:\/\/doi.org\/10.1016\/j.autrev.2021.102826","journal-title":"Autoimmun Rev"},{"key":"13283_CR13","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","volume":"43","author":"K \u015aladowska","year":"2022","unstructured":"\u015aladowska K, Kawalec P, Holko P, Osiecka O (2022) Comparative safety of high-efficacy disease-modifying therapies in relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis. Neurol Sci 43:5479\u20135500. https:\/\/doi.org\/10.1007\/s10072-022-06197-3","journal-title":"Neurol Sci"},{"key":"13283_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/jnnp-2022-330104","volume":"93","author":"C Zhu","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I et al (2022) Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 93:1330\u20131337. https:\/\/doi.org\/10.1136\/jnnp-2022-330104","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13283_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B et al (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73:790\u2013794. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"key":"13283_CR16","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:893 https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"13283_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"13283_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"13283_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"13283_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler"},{"key":"13283_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"The Lancet Neurology"},{"key":"13283_CR22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"13283_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"13283_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR (2018) A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 16:195\u2013203. https:\/\/doi.org\/10.1097\/XEB.0000000000000141","journal-title":"Int J Evid Based Healthc"},{"key":"13283_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"13283_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"13283_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"13283_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"13283_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"13283_CR30","unstructured":"Leave-one-out meta-analysis | New in Stata 17. https:\/\/www.stata.com\/stata17\/leave-one-out-meta-analysis\/. Accessed 26 Jun 2025"},{"key":"13283_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s00415-019-09195-2","volume":"266","author":"C Alcal\u00e1","year":"2019","unstructured":"Alcal\u00e1 C, Gasc\u00f3n F, P\u00e9rez-Miralles F et al (2019) Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. J Neurol 266:726\u2013734. https:\/\/doi.org\/10.1007\/s00415-019-09195-2","journal-title":"J Neurol"},{"key":"13283_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102981","volume":"52","author":"M Boudot de la Motte","year":"2021","unstructured":"Boudot de la Motte M, Louapre C, Papeix C et al (2021) Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: a monocentric study. Mult Scler Relat Disord 52:102981. https:\/\/doi.org\/10.1016\/j.msard.2021.102981","journal-title":"Mult Scler Relat Disord"},{"key":"13283_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000719","volume":"7","author":"E Ellwardt","year":"2020","unstructured":"Ellwardt E, Rolfes L, Klein J et al (2020) Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurol Neuroimmunol Neuroinflamm 7:e719. https:\/\/doi.org\/10.1212\/NXI.0000000000000719","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13283_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104564","volume":"71","author":"AU Fakih","year":"2023","unstructured":"Fakih AU, Sahraian MA, Paybast S, NaserMoghadasi A (2023) Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis. Mult Scler Relat Disord 71:104564. https:\/\/doi.org\/10.1016\/j.msard.2023.104564","journal-title":"Mult Scler Relat Disord"},{"key":"13283_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00415-021-10708-1","volume":"269","author":"D Ferraro","year":"2022","unstructured":"Ferraro D, Iaffaldano P, Guerra T et al (2022) Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. J Neurol 269:1463\u20131469. https:\/\/doi.org\/10.1007\/s00415-021-10708-1","journal-title":"J Neurol"},{"key":"13283_CR36","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.neurol.2023.03.028","volume":"179","author":"S Gassama","year":"2023","unstructured":"Gassama S, Garmendia A, Lejeune FX et al (2023) A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation. Rev Neurol (Paris) 179:1035\u20131038. https:\/\/doi.org\/10.1016\/j.neurol.2023.03.028","journal-title":"Rev Neurol (Paris)"},{"key":"13283_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200231","volume":"11","author":"L Graille-Avy","year":"2024","unstructured":"Graille-Avy L, Boutiere C, Rigollet C et al (2024) Effect of prior treatment with fingolimod on early and late response to Rituximab\/Ocrelizumab in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 11:e200231. https:\/\/doi.org\/10.1212\/NXI.0000000000200231","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13283_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103812","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skatteb\u00f8l L et al (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 62:103812. https:\/\/doi.org\/10.1016\/j.msard.2022.103812","journal-title":"Mult Scler Relat Disord"},{"key":"13283_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001183","volume":"9","author":"WM Rowles","year":"2022","unstructured":"Rowles WM, Hsu W-Y, McPolin K et al (2022) Transitioning from S1P receptor modulators to B cell-depleting therapies in multiple sclerosis: clinical, radiographic, and laboratory data. Neurol Neuroimmunol Neuroinflamm 9:e1183. https:\/\/doi.org\/10.1212\/NXI.0000000000001183","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13283_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/13524585211005657","volume":"28","author":"E Signoriello","year":"2022","unstructured":"Signoriello E, Lus G, Bonavita S et al (2022) Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Mult Scler 28:93\u2013101. https:\/\/doi.org\/10.1177\/13524585211005657","journal-title":"Mult Scler"},{"key":"13283_CR41","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1177\/13524585211049986","volume":"28","author":"M Zhong","year":"2022","unstructured":"Zhong M, van der Walt A, Stankovich J et al (2022) Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Mult Scler 28:958\u2013969. https:\/\/doi.org\/10.1177\/13524585211049986","journal-title":"Mult Scler"},{"key":"13283_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ibneur.2021.08.003","volume":"11","author":"MZI Asha","year":"2021","unstructured":"Asha MZI, Al-Asaad Y, Khalil SFH (2021) The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: a network meta-analysis. IBRO Neurosci Rep 11:103\u2013111. https:\/\/doi.org\/10.1016\/j.ibneur.2021.08.003","journal-title":"IBRO Neurosci Rep"},{"key":"13283_CR43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-022-00961-x","volume":"36","author":"X Wu","year":"2022","unstructured":"Wu X, Tan X, Zhang J et al (2022) The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. CNS Drugs 36:1155\u20131170. https:\/\/doi.org\/10.1007\/s40263-022-00961-x","journal-title":"CNS Drugs"},{"key":"13283_CR44","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","volume":"80","author":"I Roos","year":"2023","unstructured":"Roos I, Hughes S, McDonnell G et al (2023) Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 80:789\u2013797. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1625","journal-title":"JAMA Neurol"},{"key":"13283_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-025-02766-3","author":"N Mounir","year":"2025","unstructured":"Mounir N, Shalaby N, Hegazy MI et al (2025) Efficacy of ocrelizumab versus rituximab in patients with relapsing-remitting multiple sclerosis. Acta Neurol Belg. https:\/\/doi.org\/10.1007\/s13760-025-02766-3","journal-title":"Acta Neurol Belg"},{"key":"13283_CR46","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P et al (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87:2074\u20132081. https:\/\/doi.org\/10.1212\/WNL.0000000000003331","journal-title":"Neurology"},{"key":"13283_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102918","volume":"51","author":"V Pantazou","year":"2021","unstructured":"Pantazou V, Pot C, Du Pasquier R et al (2021) Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Multiple Scler Related Disord 51:102918. https:\/\/doi.org\/10.1016\/j.msard.2021.102918","journal-title":"Multiple Scler Related Disord"},{"key":"13283_CR48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.22426","volume":"69","author":"JA Cohen","year":"2011","unstructured":"Cohen JA, Chun J (2011) Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69:759\u2013777. https:\/\/doi.org\/10.1002\/ana.22426","journal-title":"Ann Neurol"},{"key":"13283_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100978","author":"MA Rocca","year":"2024","unstructured":"Rocca MA, Preziosa P, Barkhof F et al (2024) Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. Lancet Reg Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100978","journal-title":"Lancet Reg Health Eur"},{"key":"13283_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2214\/AJR.21.27069","volume":"219","author":"\u00c0 Rovira","year":"2022","unstructured":"Rovira \u00c0, Auger C (2022) Routine gadolinium use for MRI follow-up of multiple sclerosis: counterpoint\u2014gadolinium should not always be used to assess disease activity. Am J Roentgenol 219:26\u201327. https:\/\/doi.org\/10.2214\/AJR.21.27069","journal-title":"Am J Roentgenol"},{"key":"13283_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","volume":"15","author":"M Filippi","year":"2016","unstructured":"Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292\u2013303. https:\/\/doi.org\/10.1016\/S1474-4422(15)00393-2","journal-title":"Lancet Neurol"},{"key":"13283_CR52","doi-asserted-by":"publisher","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","volume":"93","author":"MD Goldman","year":"2019","unstructured":"Goldman MD, LaRocca NG, Rudick RA et al (2019) Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology 93:e1921\u2013e1931. https:\/\/doi.org\/10.1212\/WNL.0000000000008519","journal-title":"Neurology"},{"key":"13283_CR53","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/s41598-023-40940-w","volume":"13","author":"J Ingwersen","year":"2023","unstructured":"Ingwersen J, Masanneck L, Pawlitzki M et al (2023) Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci Rep 13:15003. https:\/\/doi.org\/10.1038\/s41598-023-40940-w","journal-title":"Sci Rep"},{"key":"13283_CR54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B et al (2020) Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol 19:998\u20131009. https:\/\/doi.org\/10.1016\/S1474-4422(20)30342-2","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13283-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T02:39:55Z","timestamp":1756607995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13283-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13283"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13283-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"546"}}